ESF-EMBO Symposium
Synthetic Biology of

Antibiotic Production

Hotel Eden Roc, Sant Feliu de Guixols (Costa Brava)
2-7 October 2011
Chair: Eriko Takano,
Microbial Physiology, University of Groningen,

Co-Chairs: Roel Bovenberg, DSM Biotechnology Center, Delft, NL
and Centre for Synthetic Biology, University of Groningen, NL; Rainer
Breitling, Groningen Bioinformatics Centre, University of Groningen,
NL and Institute of Molecular, Cell & Systems Biology, University of
Glasgow, UK

With support from:

DSM – the Life Sciences and
Materials Sciences Company
Sunday 2 October
Monday 3 October
Session 1: General Synthetic Biology 1
Chair: Name, Affiliation – to be confirmed
Roy Kishony
Harvard University, US
The ecology of antibiotics
Christina Smolke
Stanford, US
Molecular controllers and their application in advancing
metabolic pathway design in yeast

Tobias Bollenbach IST, Austria Resolution of gene regulatory conflicts caused by combinations of antibiotics Markus Schmidt
Biosafety and Public Dialogue in Synthetic Biology
Barry Canton Ginkgo BioWorks, US A pipeline for organism engineering at Ginkgo BioWorks Rebecca Jane Miriam Goss
University of East Anglia, UK
Elucidating and Exploiting Biosynthesis: Synthetic
Biology Approaches to Access Novel Uridyl Peptide

Alfonso Jaramillo Institute of Systems and Synthetic Biology, FR Engineering and characterization of novel regulatory elements to control gene expression in E. coli Session 2: General Synthetic Biology 2
Chair: Name, Affiliation – to be confirmed
Luis Serrano
A quantitative systems biology study on a model

Nili Ostrov Columbia University, US Cell Engineering via Reiterative Recombination in Yeast Todd Peterson Life Technologies Corp, US Design, synthesis, assembly technologies for synthetic biology engineering Jörg Stelling
Computational design of synthetic gene circuits
Eric Tippmann Cardiff University, UK New approaches for the optimization of translational and post-translational modification of proteins 1 min. Poster presentations (Poster 1-16) Tuesday 4 October
Session 3: Filamentous Fungal Systems 1
Chair: Name, Affiliation – to be confirmed
Nancy Keller
University of Wisconsin-Madison, US
Unlocking the fungal treasure chest
Sabine Albermann Westfaelische Wilhelms-Universitaet, DE Approaches for directed strain improvement targeting enhanced biosynthesis of gibberellic acid in Fusarium fujikuroi Russell Cox University of Bristol, UK Reprogramming Fungal Polyketide Synthases Axel Brakhage
Activation of fungal silent gene clusters
Jan A.K.W. Kiel University of Groningen, NL Secondary metabolism in filamentous fungi: there is more to it than just the cytosol Fungal survival strategies against antibiotics Stefan Olsson University of Copenhagen, DK Exploring fungal-bacterial interactions for discovering new bioactive substances and their mechanisms of action Session 4: Filamentous Fungal Systems 2
Chair: Name, Affiliation – to be confirmed
Jens Nielsen
Chalmers University of Technology, SE
Synthetic Biology Tools for Improving Fungal
Production of Antibiotics

Arthur Ram Leiden University, NL Secondary metabolite production in Aspergillus niger at near zero specific growth rates Daniel Scharf Leibniz Institute for Natural Product Research and Infection Biology e.V., DE Gliotoxin pathway reconstruction as a prerequisite for pathway engineering Tom Simpson University of Bristol, UK Biosynthesis and Mutasynthesis of Trans-AT Polyketides: Mupirocin and Thiomarinol Joseph Strauss BOKU University and Austrian Institute of Technology, AT Histone H3 de-methylases are involved in regulating primary and secondary metabolism 1 min. poster presentation (Posters 17-32) Wednesday 5 October
Chair: Name, Affiliation – to be confirmed
Mohamed Marahiel
University of Marburg, DE
Structural insights into the NRPS assembly machinery
Christopher Corre University of Warwick, UK New chemical keys to unlock the production of novel microbial antibiotics Anna Eliasson Lantz Technical University of Denmark, DK Application of Synthetic Promoter Library for modulation of actinorhodin production in Streptomyces coelicolor Rolf Mueller
Saarland University, DE
Title to be confirmed
Juan Pablo Gomez-Escribano John Innes Centre, UK Engineering Streptomyces coelicolor for the expression of heterologous gene clusters Luciana Gonzaga De Oliveira University of Campinas, BR Molecular fingerprint in actinomycetes Mycelium differentiation and antibiotic production in liquid cultures of Streptomyces: Biotechnological applications Justin Nodwell McMaster University, CA Remodeling secondary metabolism with synthetic chemical signals Session 6: Actinomyces Systems 2
Chair: Name, Affiliation – to be confirmed
Peter Leadlay
Cambridge University, UK
Defining modularity in polyketide synthase-containing

Hiroyasu Onaka Toyama Prefectural University, JP Biosynthesis and genetic engineering of goadsporin, one of thiazole and oxazole containing peptides (TOPs) produced by Streptomyces sp. TP-A0584 Wolfgang Wohlleben
Tübingen University, DE
Supply of building blocks for antibiotic biosynthesis
Bohdan Ostash Ivan Franko National Univerisyt of Lviv, UA Exploring and exploiting moenomycin biosynthesis to develop new class of antibiotics: contributions of genomics Hrvoje Petkovic Acies Bio, Ltd., SI New insights into substrate supply and regulation of FK506 biosynthesis and their implications for bioprocess development and drug discovery Sergey Zotchev Norwegian University of Science and Technology, NO Genome mining of marine actinobacteria for secondary metabolite biosynthesis gene clusters: tools and applications 1 min. poster presentations (Posters 33-48) Thursday 6 October
Session 7: Tools and Host Structures 1
Chair: Name, Affiliation – to be confirmed
Arnold Driessen
University of Groningen, NL
Secondary metabolite formation by Penicillium

Haruo Ikeda
Engineered streptomyces host for heterologous expression of secondary metabolism Julia Bandow Ruhr-Universität Bochum, DE Beyond Identification of Antimicrobial Compounds: Elucidating Antibiotic Mechanisms of Action Beatrix Suess
Frankfurt University, DE
Engineered riboswitches - an alternative means to
control gene expression

Michael Fischbach
A gene-to-molecule approach to the discovery and
characterization of natural products

Chemically coded two-step synthesis of lactones Ana Lorena Arabolaza Instituto de Biología Molecular y Celular de Rosario-CONICET, AR Cell host design for the production of malonyl-CoA based compounds Marnix H Medema University of Groningen, NL Automated Mining and Synthetic Biology Implementation of Secondary Metabolite Biosynthesis Gene Clusters Engineering a Natural Product Chemicopia Session 8: Tools and Host Structures 2
Chair: Name, Affiliation – to be confirmed
Kristala Jones Prather
Parts, devices, and chassis in support of metabolic

Anne-Gaëlle Planson University of Evry, FR Therapeutic production in Escherichia coli using retrosynthetic design of metabolic pathways Christian Rausch Royal DSM N.V., NL NRPSpredictor2: an established method for the prediction of NRPS adenylation domain specificity – update and examples of applications Adam Spargo University of Exeter, UK Rule-based simulation of synthetic integron construction Colin Lazarus University of Bristol, UK Molecular systems development for studying and manipulating natural product biosynthesis Antonio Starcevic University of Zagreb, Zagreb, Croatia Modelling of homologous recombination in modular polyketide synthases combined with synthetic biology as a strategy for producing biologically active lead compounds Chris Voigt
Refactoring Prokaryotic Gene Clusters Forward Look Plenary Discussion
Friday 7 October


Microsoft word - ka1330-600310

Background Lysosomes are single membrane-bound acidic intracellular compartments that break down cellular waste products, fats, carbohydrates, proteins, and other macromolecules into simple compounds. Normal lysosome function enables cells to efficiently mobilize and recycle cellular constituents, but also prevents the accumulation of damaged organelles, misfolded proteins, and invading mic

A pragmatic and cost-effective strategy of a combination therapy of interferon alpha-2b and ribavirin for the treatment of chronic hepatitis c

A pragmatic and cost-effective strategy of a combinationtherapy of interferon alpha-2b and ribavirin for the treatmentMarkus Sagmeistera,b, John B. Wongb, Beat Mullhauptc andBackground Combination of interferon (IFN) alpha andcombination therapy dominates all other strategies. Inribavirin is considered the standard treatment for patientsgenotype 1 infection, 48 weeks of combination therapy f

Copyright © 2010-2014 Drug Shortages pdf